Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management

Area of Science:

• Oncology
• Melanoma Research
• Surgical Pathology

Background:

• Extracapsular spread (ECS) is a known high-risk factor in melanoma with macrometastatic (N+) nodal disease.
• The prognostic significance of ECS in sentinel lymph node (SLN) biopsy for micrometastatic stage III melanoma remains unclear.

Purpose of the Study:

• To investigate the incidence of ECS in melanoma patients with nodal involvement.
• To determine the prognostic value of ECS in both SLN biopsy and N+ nodal disease.

Main Methods:

• Retrospective analysis of 515 patients with micro/macrometastatic lymphadenopathy undergoing nodal surgery (2008-2014).
• Data collected included patient demographics, tumor characteristics, nodal ECS status, and patient outcomes.
• Multivariate analysis was used to assess prognostic indicators.

Main Results:

• ECS was more frequent in N+ disease (52.4%) than SLN+ disease (16.2%).
• ECS in SLN+ patients significantly reduced 10-year disease-specific survival (DSS) by ~30% (37.2% vs. 66.2%).
• ECS status was an independent prognostic indicator for DSS in SLN+ disease (HR 2.47).

Conclusions:

• Extracapsular spread is a significant prognostic indicator for DSS, progression-free survival, and overall survival in both SLN+ and N+ melanoma.
• ECS upstages stage III melanoma, comparable to ulceration in stage I/II disease.
• A simplified staging system using ECS instead of N stage can accurately predict patient prognosis.